CA2505373A1 - Procedes d'utilisation de composes de vitamine d pour traiter des syndromes myelodysplasiques - Google Patents

Procedes d'utilisation de composes de vitamine d pour traiter des syndromes myelodysplasiques Download PDF

Info

Publication number
CA2505373A1
CA2505373A1 CA002505373A CA2505373A CA2505373A1 CA 2505373 A1 CA2505373 A1 CA 2505373A1 CA 002505373 A CA002505373 A CA 002505373A CA 2505373 A CA2505373 A CA 2505373A CA 2505373 A1 CA2505373 A1 CA 2505373A1
Authority
CA
Canada
Prior art keywords
vitamin
compounds
administered
compound
active agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002505373A
Other languages
English (en)
Inventor
Martha J. Whitehouse
John G. Curd
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novacea Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2505373A1 publication Critical patent/CA2505373A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des procédés pour traiter des syndromes myélodysplasiques ou améliorer un symptôme de ceux-ci. Des procédés spécifiques consistent à administrer un ou plusieurs composés de vitamine D ou un sel, solvate, hydrate, stéréoisomère, clathrate ou promédicament de ceux-ci, acceptable d'un point de vue pharmaceutique, seuls ou associés à un ou plusieurs agents actifs supplémentaires. D'autres procédés consistent à administrer par intermittence une haute dose d'un ou de plusieurs composés de vitamine D ou d'un sel, solvate, hydrate, stéréoisomère, clathrate ou promédicament de ceux-ci, acceptable d'un point de vue pharmaceutique, seuls ou associés à un ou plusieurs agents actifs supplémentaires. Une telle administration par intermittence permet d'administrer de hautes doses de composés de vitamine D tout en minimisant ou supprimant l'apparition d'une hypercalcémie.
CA002505373A 2002-11-06 2003-11-06 Procedes d'utilisation de composes de vitamine d pour traiter des syndromes myelodysplasiques Abandoned CA2505373A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42454602P 2002-11-06 2002-11-06
US60/424,546 2002-11-06
PCT/US2003/035244 WO2004043360A2 (fr) 2002-11-06 2003-11-06 Procedes d'utilisation de composes de vitamine d pour traiter des syndromes myelodysplasiques

Publications (1)

Publication Number Publication Date
CA2505373A1 true CA2505373A1 (fr) 2004-05-27

Family

ID=32312829

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002505373A Abandoned CA2505373A1 (fr) 2002-11-06 2003-11-06 Procedes d'utilisation de composes de vitamine d pour traiter des syndromes myelodysplasiques

Country Status (8)

Country Link
EP (1) EP1562606A4 (fr)
JP (1) JP2006508125A (fr)
KR (1) KR20050086545A (fr)
CN (1) CN100386083C (fr)
AU (1) AU2003291294A1 (fr)
CA (1) CA2505373A1 (fr)
MX (1) MXPA05004985A (fr)
WO (1) WO2004043360A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050026877A1 (en) * 2002-12-03 2005-02-03 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
AU2004247108A1 (en) * 2003-06-11 2004-12-23 Novacea, Inc Treatment of immune-mediated disorders with active vitamin D compounds alone or in combination with other therapeutic agents
EP1791547A1 (fr) * 2004-05-28 2007-06-06 Abbott Laboratories Formulations orales de paricalcitol
US8501717B2 (en) 2007-02-09 2013-08-06 Merck, Sharp & Dohme Corp. Methods to treat and/or prevent mucositis
SG173119A1 (en) * 2009-01-27 2011-08-29 Berg Biosystems Llc Vitamin d3 and analogs thereof for alleviating side effects associated with chemotherapy
CN103142478B (zh) * 2013-03-21 2014-10-01 青岛正大海尔制药有限公司 骨化三醇乳剂及其制备方法
CN109864992B (zh) * 2017-12-01 2021-07-27 暨南大学 维生素D3或其活性形式1α,25(OH)2D3在抑制PD-1表达中的应用
CN111228301A (zh) * 2020-01-14 2020-06-05 哈尔滨医科大学 一种用于治疗血管生成介导疾病的复方制剂及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040009958A1 (en) * 1991-01-08 2004-01-15 Bone Care International, Inc. Methods for preparation and use of 1alpha,24(S)-dihydroxyvitamin D2
JP2002509888A (ja) * 1998-03-27 2002-04-02 オレゴン ヘルス サイエンシーズ ユニバーシティー 腫瘍および他の過増殖性疾患の治療におけるビタミンｄおよびその類似体
AU2002363959B2 (en) * 2001-12-03 2007-12-13 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
WO2004110151A1 (fr) * 2003-06-11 2004-12-23 Novacea, Inc. Traitement du cancer au moyen de composes de vitamine d actifs associes a des agents et a des traitements radiotherapeutiques

Also Published As

Publication number Publication date
WO2004043360A3 (fr) 2004-10-14
MXPA05004985A (es) 2005-08-02
CN100386083C (zh) 2008-05-07
KR20050086545A (ko) 2005-08-30
EP1562606A4 (fr) 2006-05-24
AU2003291294A1 (en) 2004-06-03
EP1562606A2 (fr) 2005-08-17
WO2004043360A2 (fr) 2004-05-27
JP2006508125A (ja) 2006-03-09
CN1732009A (zh) 2006-02-08

Similar Documents

Publication Publication Date Title
US20070027120A1 (en) Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes
ES2211107T3 (es) 1-alfa-hidroxi-25-eno-vitamina d, analogos y utilizaciones de los mismos.
US8501717B2 (en) Methods to treat and/or prevent mucositis
US5795882A (en) Method of treating prostatic diseases using delayed and/or sustained release vitamin D formulations
AU723835B2 (en) Method of treating prostatic diseases using active vitamin D analogues
JP2005510536A (ja) 活性ビタミンｄ類縁物質を使用した過剰増殖性疾病の治療
KR20050044655A (ko) 활성 비타민 ｄ 화합물을 함유하는 약제학적 조성물
CA2517160A1 (fr) Procede de traitement et de prevention de l'hyperparathyroidie par des composes vitaminiques
JP2010536866A (ja) ビタミンｄ化合物の用量範囲を拡張する方法
AU2010261967B2 (en) New therapeutical uses of inecalcitol
CA2505373A1 (fr) Procedes d'utilisation de composes de vitamine d pour traiter des syndromes myelodysplasiques
UA110211C2 (uk) Нові склади 14-eпi-аналогів вітаміну d
MXPA00011215A (en) 1&agr;-HYDROXY-25-ENE-VITAMIN D, ANALOGS AND USES THEREOF
WO2012128653A1 (fr) Utilisation d'anastrozole et d'analogue de vitamine d dans polythérapie contre le cancer du sein

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued
FZDE Discontinued

Effective date: 20101108